Cardiol Therapeutics Inc. (FRA:CT9)

Market Cap	95.59M -15.8%
Revenue (ttm)	n/a
Net Income	-21.28M
EPS	-0.26
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	16
Open	0.8010
Previous Close	0.8140
Day's Range	0.8010 - 0.8010
52-Week Range	0.6000 - 1.3680
Beta	n/a
RSI	49.21
Earnings Date	Mar 27, 2026

About Cardiol Therapeutics

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical develop...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2017
• Employees: 18
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: CT9

Financial Performance

Financial numbers in CAD